Forcefield Therapeutics Ltd.

“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office

“We’ve seen some tremendous acceleration in science over the past few years and that science is the driving force behind new medicines. The fundamental need for these new medicines is the underpinning

Executive changes in the off-patent medicines industry throughout 2023 reflected a growing interest in the innovator side of the life sciences sector among leading generics and biosimilars companies.

Dmitrij Hristodorov, partner at Forbion, told the Sachs Forum audience there were clear signs of a comeback for the cardiovascular/cardiometabolic (CVM) market. He highlighted new drug approvals in dy